NTQ2494 / Sino Biopharm - LARVOL DELTA

Discovery of NTQ2494, a potent and orally bioavailable inhibitor of AXL kinase for the treatment of human tumors. (PubMed, Eur J Med Chem) - "NTQ2494 (5p) exhibited favorable ADMET properties and demonstrated significantly enhanced in vivo efficacy in an MV-4-11 xenograft model compared to TP-0903. NTQ2494 is currently under Phase I clinical evaluation for the treatment of advanced hematological malignancies and solid tumors."

Journal • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • AXL

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical

Metastases • New P1 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology